HLX319

DRUG2 trials

Sponsors

Shanghai Henlius Biotech

Conditions

HER2 + Breast CancerHealth Adult Subjects

Phase 1

Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®

Not yet recruitingNCT07495930

Shanghai Henlius BiotechHealth Adult Subjects

Start: 2026-04-30End: 2026-10-10Target: 24Updated: 2026-04-01

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

Not yet recruitingNCT07601620

Shanghai Henlius BiotechHER2 + Breast Cancer

Start: 2026-07-03End: 2027-07-22Target: 258Updated: 2026-05-22